Concurrence of imatinib-induced massive pleural/pericardial effusion and Campylobacter bacteremia in an adolescent with chronic myeloid leukemia
Open Access
- 11 October 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Infection and Chemotherapy
- Vol. 28 (1), 103-107
- https://doi.org/10.1016/j.jiac.2021.10.002
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 MacrophagesThe Journal of Immunology, 2017
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2017
- Campylobacterbacteremia: A rare and under-reported event?European Journal of Microbiology and Immunology, 2012
- Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemiaLeukemia, 2009
- Campylobacter infections of the pericardium and myocardiumClinical Microbiology & Infection, 2005
- Pleural‐pericardic effusion as uncommon complication in CML patients treated with ImatinibEuropean Journal of Haematology, 2004
- Campylobacter jejuni Infections: Update on Emerging Issues and TrendsClinical Infectious Diseases, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2001
- Differential uptake and killing potential of Campylobacter jejuni by human peripheral monocytes/macrophagesMedical Microbiology and Immunology, 1997
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981